TL;DR
This study validates a multi-ancestry polygenic risk score (PRS) for prostate cancer, demonstrating its effectiveness in stratifying risk across European, African, and Hispanic populations. The PRS shows a significant association with prostate cancer risk, with its predictive power diminishing with increasing age, suggesting a need for age-specific risk assessment in screening strategies.
What Problem Does This Paper Address?
Prostate cancer is a significant health concern, particularly for African ancestry men who experience higher incidence rates. While genetic factors play a crucial role in susceptibility, existing polygenic risk scores (PRS) have often been developed and validated primarily in European ancestry populations, potentially limiting their utility in diverse groups. Furthermore, the interplay between genetic risk and age in prostate cancer development is not fully understood, complicating risk stratification and screening recommendations. This paper addresses the need for a validated, multi-ancestry PRS that can accurately assess prostate cancer risk across different populations and considers the influence of age on this risk.
Methods
The researchers employed a meta-analysis approach to validate a previously developed multi-ancestry polygenic risk score (PRS) for prostate cancer. This PRS is based on 269 common genetic variants identified through a trans-ancestry genome-wide association study. The validation involved combining results from several independent replication studies across European, African, and Hispanic populations. For each ancestry group, the association between PRS and prostate cancer risk was evaluated separately and then pooled using a fixed-effects inverse-variance-weighted meta-analysis. To assess age-specific effects, age-stratified analyses were conducted in two large replication studies (UK Biobank and Million Veteran Program). Absolute risks of prostate cancer were then calculated for different PRS categories and age groups.
Datasets
The study utilized data from several large-scale datasets for validation and meta-analysis:
- Million Veteran Program (MVP): A large dataset of US veterans, including European, African, and Hispanic ancestry participants.
- UK Biobank: A large UK-based prospective cohort study with European ancestry participants.
- Mass General Brigham (MGB) Biobank: A dataset with European and African ancestry participants.
- California and Uganda Prostate Cancer Study (CA UG): A study focusing on African ancestry populations.
- Men of African Descent and Carcinoma of the Prostate (MADCaP) Network: A study on African ancestry populations.
- Maryland Prostate Cancer Case-Control Study (NCI-MD): A study on African ancestry populations.
These datasets were used to replicate the PRS's performance and to conduct age-stratified analyses.
Key Insights and Ideas
- PRS is a robust risk stratifier across ancestries: The study provides strong evidence that the multi-ancestry PRS effectively stratifies prostate cancer risk not only in European but also in African and Hispanic populations, addressing a critical gap in current PRS utility.
- Age significantly modifies PRS performance: The PRS shows a stronger association with prostate cancer risk in younger men, with its predictive power diminishing as men age. This highlights the importance of considering age alongside genetic risk for more accurate risk assessment.
- Potential for improved screening strategies: The age-specific risk estimates derived from the PRS could inform personalized screening guidelines, potentially reducing overdiagnosis in lower-risk individuals and ensuring timely detection in higher-risk men.
- Need for continued research in underrepresented populations: While the PRS performs well across ancestries, the study notes consistently lower performance in African ancestry men, underscoring the ongoing need for larger GWAS and fine-mapping efforts in these populations to further improve PRS accuracy.
Key Results
- The multi-ancestry PRS was strongly associated with prostate cancer risk across all three major populations studied.
- In European ancestry men, the odds ratio (OR) for the top PRS decile (90-100%) compared to the average (40-60%) was 3.8-fold. For African ancestry men, the OR was 2.8-fold, and for Hispanic men, it was 3.2-fold.
- The PRS showed a significant age-related effect modification. For European ancestry men in the top PRS decile, the OR was 7.11 for men ≤55 years, decreasing to 2.79 for men >70 years.
- Men in the top PRS decile reached a 5% absolute prostate cancer risk approximately 10 years younger than men in the average PRS category.
- The PRS did not consistently differentiate aggressive from nonaggressive prostate cancer, although some trends were observed in specific populations.
Limitations and Future Work
The authors acknowledge that the PRS performance was consistently lower in African ancestry men compared to European ancestry men, reinforcing the need for expanded GWAS and fine-mapping efforts in African populations. While the study demonstrates the PRS's effectiveness in risk stratification, they suggest that a clinical study is warranted to determine its utility in risk-stratified screening and early detection. The study also notes that the PRS did not consistently differentiate aggressive from nonaggressive prostate cancer, which could be a focus for future research. The authors also highlight the potential for PRS-stratified screening to reduce overdiagnosis, particularly in men with lower genetic risk, and call for further studies to evaluate the clinical utility of this multi-ancestry PRS in diverse populations for shared decision-making in prostate cancer screening.
Summary updated